REDWOOD CITY, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional states in the US that are key to driving faster adoption of its flagship product, Bioflux. The Company has been experiencing great traction with its technology in the marketplace and is taking the opportunity to capitalize on its momentum and increase its regional footprint. Biotricity is confident that broadening its influence through expansion in high growth sectors will help accelerate sales, drive revenue, and develop market share.
“Our Bioflux was met with a high adoption rate in the clinical community throughout our soft launch over the past year,” said Casey Shattuck, Biotricity Global VP of Sales. “From a sales perspective, I have tremendous confidence in our expansion based on the overwhelmingly positive customer feedback we’ve received and our re-order rates thus far.”
The Company’s remote patient monitoring device Bioflux monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.
“Our expansion comes on the heels of great reception in other states,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “We have secured loyal anchor clients in key industry markets with great customer feedback. This has bolstered our confidence and we believe we are well placed to grow and to kick off the next phase of the Company.”
Biotricity is growing its presence in the connected-health market; an estimated 36 million patients are expected to be equipped with remote monitoring devices by 2020. With Bioflux, Biotricity believes doctors will have unprecedented levels of relevancy and timeliness to patient ECG information.
To learn more, visit www.biotricity.com or follow on:
Twitter: @biotricity_inc Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com